Abstract
The pathophysiology of sodium and water retention in heart failure is complex and marked by a unique interplay of hemodynamic and neurohumoral factors that evolve in tandem with progression of the underlying heart failure state. The sense of arterial underfilling signals the heart and prompts heart failure-related sodium and water retention. The level of neurohormonal activation, the scale of renal vasoconstriction, and the degree to which renal perfusion pressure is reduced arbitrate this process. When water retention exceeds that of sodium the end result is dilutional hyponatremia, which can present a particularly tricky treatment circumstance. The edema state can also moderate assorted aspects of the natriuretic response to diuretic therapy. The blunted response to diuretics in heart failure can also have disease-specific elements; however, diuretic response is more commonly influenced by the rate and extent of diuretic absorption, the time course of tubular delivery for a diuretic and loop diuretic-related hypertrophic structural changes localized to the distal tubule.
Originally published in Bakris, The Kidney in Heart Failure, ISBN: 978-1-4614-3693-5
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med. 1999;341: 577–85.
Damman K, Navis G, Voors AA, et al. Worsening renal function and prognosis in heart failure: systematic review and meta-analysis. J Card Fail. 2007;13:599–608.
Rea ME, Dunlap ME. Renal hemodynamics in heart failure: implications for treatment. Curr Opin Nephrol Hypertens. 2008;17:87–92.
Voors AA, Davison BA, Felker GM, et al. Early drop in systolic blood pressure and worsening renal function in acute heart failure: renal results of Pre-RELAX-AHF. Eur J Heart Fail. 2011;13:961–7.
Flapan AD, Davies E, Waugh C, et al. Acute administration of captopril lowers the natriuretic and diuretic response to a loop diuretic in patients with chronic cardiac failure. Eur Heart J. 1991;12:924–7.
Cat AN, Touyz RM. A new look at the renin-angiotensin system-focusing on the vascular system. Peptides. 2011;32:2141–50.
Geerling JC, Loewy AD. Central regulation of sodium appetite. Exp Physiol. 2008;93:177–209.
Good JM, Brady AJ, Noormohamed FH, et al. Effect of intense angiotensin II suppression on the diuretic response to furosemide during chronic ACE inhibition. Circulation. 1994;90:220–4.
Schoolwerth A, Sica DA, Ballermann BJ, Wilcox CS. Renal considerations in angiotensin converting enzyme inhibitor therapy. Circulation. 2001;104:1985–91.
Kaye D, Esler M. Sympathetic neuronal regulation of the heart in aging and heart failure. Cardiovasc Res. 2005;66:256–64.
Watson AM, Hood SG, May CN. Mechanisms of sympathetic activation in heart failure. Clin Exp Pharmacol Physiol. 2006;33:1269–74.
DiBona GF. Peripheral and central interactions between the renin-angiotensin system and the renal sympathetic nerves in control of renal function. Ann N Y Acad Sci. 2001;940:395–406.
Chen HH, Schrier RW. Pathophysiology of volume overload in acute heart failure syndromes. Am J Med. 2006;119(12 Suppl 1):S11–6.
Heitmann M, Davidsen U, Stokholm KH, et al. Renal and cardiac function during alpha1-beta-blockade in congestive heart failure. Scand J Clin Lab Invest. 2002;62:97–104.
Dupont AG. Effects of carvedilol on renal function. Eur J Clin Pharmacol. 1990;38 Suppl 2: S96–100.
Ito H, Nagatomo Y, Kohno T, et al. Differential effects of carvedilol and metoprolol on renal function in patients with heart failure. Circ J. 2010;74:1578–83.
Mullens W, Abrahams Z, Francis GS, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol. 2009;53:589–96.
Agostoni P, Marenzi G, Lauri G, et al. Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med. 1994;96:191–9.
Sica DA. Sodium and water retention in heart failure and diuretic therapy: basic mechanisms. Cleveland Clin J Med. 2006;73 Suppl 2:82–7.
van Kraaij DJ, Jansen RW, Sweep FC, et al. Neurohormonal effects of furosemide withdrawal in elderly heart failure patients with normal systolic function. Eur J Heart Fail. 2003;5:47–53.
Yilmaz MB, Gayat E, Salem R, et al. Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail. 2011;13:1244–52.
Peacock WF, Costanzo MR, De Marco T, et al. ADHERE Scientific Advisory Committee and Investigators. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology. 2009;113:12–9.
Hasselblad V, Gattis SW, Shah MR, et al. Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail. 2007;9: 1064–9.
Weaver A, Sica DA. Mannitol-induced acute renal failure. Nephron. 1987;45:233–5.
Eveloff J, Warnock DG. Renal carbonic anhydrase. In: Dirks JH, Sutton RA, editors. Diuretics: physiology, pharmacology and clinical use. Philadelphia: WB Saunders; 1986. p. 49–65.
Cogan MG, Maddox DA, Warnock DG, et al. Effect of acetazolamide on bicarbonate reabsorption in the proximal tubule of the rat. Am J Physiol. 1979;237:F447.
Kassamali R, Sica DA. Acetazolamide—a forgotten diuretic agent. Cardiol Rev. 2011;19: 276–8.
Khan MI. Treatment of refractory congestive heart failure and normokalemic hypochloremic alkalosis with acetazolamide and spironolactone. Can Med Assoc J. 1980;123:883–7.
Knauf H, Mutschler E. Sequential nephron blockade breaks resistance to diuretics in edematous states. J Cardiovasc Pharmacol. 1997;29:367–72.
Mazur JE, Devlin JW, Peters MJ, et al. Single versus multiple doses of acetazolamide for metabolic alkalosis in critically ill medical patients: a randomized, double-blind trial. Crit Care Med. 1999;27:1257–61.
Leary WP, Reyes AJ. Diuretic-induced magnesium losses. Drugs. 1984;28 Suppl 1:182–7.
Kamalov G, Bhattacharya SK, Weber KT. Congestive heart failure: where homeostasis begets dyshomeostasis. J Cardiovasc Pharmacol. 2010;56:320–8.
Beerman B, Groschinsky-Grind M. Pharmacokinetics of hydrochlorothiazide in patients with congestive heart failure. Br J Clin Pharmacol. 1979;7:579–83.
Sica DA, Gehr TWB. Diuretic combinations in refractory edema states: pharmacokinetic/pharmacodynamic relationships. Clin Pharmacokinet. 1996;30:229–49.
Rosenberg J, Gustafsson F, Galatius S, et al. Combination therapy with metolazone and loop diuretics in outpatients with refractory heart failure: an observational study and review of the literature. Cardiovasc Drugs Ther. 2005;19:301–6.
Dormans TP, Gerlag PG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J. 1996;17:1867–74.
Sica DA. Pharmacotherapy in congestive heart failure: metolazone and its role in edema management. Cong Heart Fail. 2003;9:100–5.
Shankar SS, Brater DC. Loop diuretics: from the Na-K-2Cl transporter to clinical use. Am J Physiol Renal Physiol. 2003;284:F11–21.
Liguori A, Casini A, Di Loreto M, et al. Loop diuretics enhance the secretion of prostacyclin in vitro, in healthy persons, and in patients with chronic heart failure. Eur J Clin Pharmacol. 1999;55:117–24.
Sjöström PA, Kron BG, Odlind BG. Changes in renal clearance of furosemide due to changes in renal blood flow and plasma albumin concentration. Eur J Clin Pharmacol. 1993;45:135–9.
Dixey JJ, Noormohamed FH, Pawa JS, et al. The influence of nonsteroidal anti-inflammatory drugs and probenecid on the renal response to and kinetics of piretanide in man. Clin Pharmacol Ther. 1988;44:531–9.
Brater DC. Diuretic therapy. N Engl J Med. 1998;339:387–95.
Brater DC. Pharmacokinetics of loop diuretics in congestive heart failure. Br Heart J. 1994;72 Suppl 2:S40–3.
Murphy CA, Dargie HJ. Drug-induced cardiovascular disorders. Drug Saf. 2007;30: 783–804.
Heerdink ER, Leufkens HG, Herings RM, et al. NSAIDs associated with increased risk of congestive heart failure in elderly patients taking diuretics. Arch Intern Med. 1998;158:1108–12.
Murray MD, Haag KM, Black PK, et al. Variable furosemide absorption and poor predictability of response in elderly patients. Pharmacotherapy. 1997;17:98–106.
Vargo DL, Kramer WG, Black PK, et al. Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart failure. Clin Pharmacol Ther. 1995;57:601–9.
Murray MD, Deer MM, Ferguson JA, et al. Open-label randomized trial of torsemide compared with furosemide therapy for patients with heart failure. Am J Med. 2001;111:513–20.
Sica DA, Gehr TW. Diuretic use in stage 5 chronic kidney disease and end-stage renal disease. Curr Opin Nephrol Hypertens. 2003;12:483–90.
Maschio G, D’Angelo A, Fabris A, et al. Long-term effects of low-dose thiazide and amiloride administration in recurrent renal stone formers. Contrib Nephrol. 1985;49:108–17.
Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21.
Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11–21.
Gardiner P, Schrode K, Quinlan D, et al. Spironolactone metabolism: steady-state serum levels of the sulfur-containing metabolites. J Clin Pharmacol. 1989;29:342–7.
Reyes AJ, Leary WP, Crippa G, et al. The aldosterone antagonist and facultative diuretic eplerenone: a critical review. Eur J Intern Med. 2005;16:3–11.
Cheitlin MD, Byrd R, Benowitz N, et al. Amiloride improves hemodynamics in patients with chronic congestive heart failure treated with chronic digoxin and diuretics. Cardiovasc Drugs Ther. 1991;5:719–25.
Zheng H, Liu X, Rao US, et al. Increased renal ENaC subunits and sodium retention in rats with chronic heart failure. Am J Physiol Renal Physiol. 2011;300:F641–9.
Kohvakka A. Maintenance of potassium balance during long-term diuretic therapy in chronic heart failure patients with thiazide-induced hypokalemia: comparison of potassium supplementation with potassium chloride and potassium-sparing agents, amiloride and triamterene. Int J Clin Pharmacol Ther Toxicol. 1988;26:273–7.
Favre L, Glasson P, Vallotton MB. Reversible acute renal failure from combined triamterene and indomethacin: a study in healthy subjects. Ann Intern Med. 1982;96:317–20.
Torp M, Brønd L, Nielsen JB, et al. Effects of renal denervation on the NKCC2 co-transporter in the thick ascending limb of the loop of Henle in rats with congestive heart failure. Acta Physiol (Oxf). 2011. doi:10.1111/j.1748-1716.2011.02351.x [Epub ahead of print]
Vasko MR, Brown-Cartwright D, Knochel JP, et al. Furosemide absorption altered in decompensated congestive heart failure. Ann Intern Med. 1985;102:314–8.
Sandek A, Bauditz J, Swidsinski A, et al. Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol. 2007;50:1561–9.
Addisu A, Gower Jr WR, Serrano M, et al. Heart failure mice exhibit decreased gastric emptying and intestinal absorption. Exp Biol Med (Maywood). 2011;236:1454–60.
Kelly RA, Wilcox CS, Mitch WE, et al. Response of the kidney to furosemide. II. Effect of captopril on sodium balance. Kidney Int. 1983;24:233–9.
Wilcox CS, Guzman NJ, Mitch WE, et al. Na+ and BP homeostasis in man during furosemide: effects of prazosin and captopril. Kidney Int. 1987;31:135–41.
Almeshari K, Ahlstom NG, Capraro FE, et al. A volume-independent component to post-diuretic sodium retention in man. J Am Soc Nephrol. 1993;3:1878–83.
Ellison DH, Velazquez H, Wright FS. Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion. J Clin Invest. 1989;83:113–26.
Wilcox CS, Mitch WE, Kelly RA, et al. Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med. 1983;102:450–8.
Abdallah JG, Schrier RW, Edelstein C, et al. Loop diuretic infusion increases thiazide-sensitive Na(+)/Cl(−)-cotransporter abundance: role of aldosterone. J Am Soc Nephrol. 2001;12: 1335–41.
Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int. 1989;36:682–9.
Ellison DH. The physiologic basis of diuretic synergism: its role in treating diuretic resistance. Ann Intern Med. 1991;114:886–94.
Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev. 2004;1:CD003178.
Dikshit K, Vyden JK, Forrester JS, et al. Renal and extrarenal hemodynamic effects of furosemide in congestive heart failure after acute myocardial infarction. N Engl J Med. 1973;288: 1087–90.
Kramer BK, Schweda F, Riegger GAJ. Diuretic treatment and diuretic resistance in heart failure. Am J Med. 1999;106:90–6.
Flapan AD, Davies E, Waugh C, et al. Posture determines the nature of the interaction between angiotensin converting enzyme inhibitors and loop diuretics in patients with chronic cardiac failure. Int J Cardiol. 1991;33:377–83.
Galiwango PJ, McReynolds A, Ivanov J, et al. Activity with ambulation attenuates diuretic responsiveness in chronic heart failure. J Card Fail. 2011;17:797–803.
Galve E, Malloi A, Catalan R, et al. Clinical and neurohumoral consequences of diuretic withdrawal in patients with chronic, stabilized, heart failure and systolic dysfunction. Eur J Heart Fail. 2005;7:892–8.
Marangoni E, Oddone A, Surian M, et al. Effect of high-dose furosemide in refractory congestive heart failure. Angiology. 1990;41:862–8.
Gerlag PG, van Meijel JJ. High-dose furosemide in the treatment of refractory congestive heart failure. Arch Intern Med. 1988;148:286–91.
Rudy DW, Voelker JR, Greene PK, et al. Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med. 1991;115:360–6.
Lahav M, Regev A, Ra’anani P, et al. Intermittent administration of furosemide vs. continuous infusion preceded by a loading dose for congestive heart failure. Chest. 1992;102:725–31.
Felker GM, Lee KL, Bull DA, et al. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011;364:797–805.
Jentzer JC, DeWald TA, Hernandez AF. Combination of loop diuretics with thiazide-type diuretics in heart failure. J Am Coll Cardiol. 2010;56:1527–34.
Barr CS, Lang CC, Hanson J, et al. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259–65.
Farquharson CAJ, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation. 2000;101:594–7.
Weber KT. Aldosterone in congestive heart failure. N Engl J Med. 2001;345:1689–97.
Pitt B, Zannad F, Rime WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709–17.
Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O’Brien T, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. J Card Fail. 2011;17:973–81.
Costanzo MR, Jessup M. Treatment of congestion in heart failure with diuretics and extracorporeal therapies: effects on symptoms, renal function and prognosis. Heart Fail Rev. 2011 [Epub ahead of print]
Cpstanzo MR, Guglin ME, Saltzverg MT, et al. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol. 2007;49:675–83.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media New York
About this chapter
Cite this chapter
Sica, D.A. (2012). Edema Mechanisms in the Heart Failure Patient and Treatment Options. In: Bakris, G. (eds) Managing the Kidney when the Heart is Failing. Springer, Boston, MA. https://doi.org/10.1007/978-1-4614-3691-1_6
Download citation
DOI: https://doi.org/10.1007/978-1-4614-3691-1_6
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4614-3690-4
Online ISBN: 978-1-4614-3691-1
eBook Packages: MedicineMedicine (R0)